
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1083 | 972 | 1083 | 1021 | 1170 | 1743 |
Fund Return | 8.29% | -2.76% | 8.29% | 0.69% | 3.18% | 5.71% |
Place in category | 100 | 31 | 100 | 35 | 314 | 103 |
% in Category | 15 | 5 | 15 | 6 | 67 | 34 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
UBS CH Institutional Fund 2 EquiP2X | 8.25B | 0.98 | 11.71 | 12.36 | ||
UBS CH Institutional Fund 2 EquiPAX | 4.34B | 2.19 | 10.23 | 9.88 | ||
UBS CH Vitainvest 50 World U | 4.29B | 7.32 | -1.50 | 2.35 | ||
UBS CH Institutional Fund 2 EquiSCA | 2.93B | 3.61 | 3.69 | 7.88 | ||
UBS CH Institutional Fund 2 EquiSCX | 2.93B | -0.41 | 2.98 | 6.78 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CH0033782431 | 2.72B | 12.09 | 5.90 | 7.10 | ||
Pictet CH Institutional Swiss EquiI | 2.29B | 10.19 | 3.38 | 7.31 | ||
Pictet CH Institutional Swiss EquZD | 2.29B | 10.28 | 3.87 | 7.82 | ||
Pictet CH Institutional Swiss EquiP | 2.29B | 10.16 | 3.18 | 7.09 | ||
Pictet CH Institutional Swiss EquiZ | 2.29B | 8.90 | 2.54 | 8.57 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Nestle | CH0038863350 | 9.50 | 89.60 | -2.27% | |
Novartis | CH0012005267 | 9.22 | 98.12 | -1.12% | |
UBS Group | CH0244767585 | 9.04 | 29.09 | +1.01% | |
Roche Holding Participation | CH0012032048 | 9.03 | 304.20 | -1.62% | |
Zurich Insurance Group | CH0011075394 | 8.87 | 611.60 | +0.10% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review